Mereo BioPharma stock steadies premarket as JPM Healthcare Conference puts MREO back in play
Mereo BioPharma shares hovered near $0.49 in U.S. premarket trading Monday after a 28.6% surge Friday, following recent trial failures for its lead drug setrusumab. CEO Denise Scots-Knight will present at the J.P. Morgan Healthcare Conference on Jan. 14, as investors watch for updates on spending cuts and partnering talks for alvelestat.
